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Abstract  Inﬂammatory  bowel  diseases  (IBD)  are  associated  with  an  increased  risk  of  gas-
trointestinal  cancers  and  more  speciﬁcally  in  sites  affected  by  chronic  inﬂammation.  However,
patients with  IBD  have  also  an  increased  risk  for  developing  a  variety  of  extra-intestinal  cancers.
In this  regard,  hepatobiliary  cancers,  such  as  cholangiocarcinoma,  are  more  frequently  observed
in IBD  patients  because  of  a  high  prevalence  of  primary  sclerosing  cholangitis,  which  is  consid-
ered as  a  favoring  condition.  Extra-intestinal  lymphomas,  mostly  non-Hodgkin  lymphomas,  and
skin cancers  are  also  observed  with  an  increased  incidence  in  IBD  patients  by  comparison  with
that in  patients  without  IBD.  This  review  provides  an  update  on  demographics,  risk  factors  and
clinical features  of  extra-intestinal  malignancies,  including  cholangiocarcinoma,  hepatocellular
carcinoma  and  lymphoma,  that  occur  in  patients  with  IBD  along  with  a  special  emphasis  on  the
multidetector  row  computed  tomography  and  magnetic  resonance  imaging  features  of  these
uncommon conditions.
© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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tnﬂammatory  bowel  diseases  (IBD),  which  include  Crohn’s
isease  (CD)  and  ulcerative  colitis  (UC),  are  characterized
y  chronic  inﬂammation  of  the  gastrointestinal  tract  [1—3].
astrointestinal  cancers  are  of  major  concern  in  the  follow-
p  of  IBD  patients,  so  that  they  have  already  received  a
reat  attention  in  the  gastroenterological  and  radiological
iteratures  [4—9].  However,  although  they  are  somewhat
arer,  extra-intestinal  malignancies  associated  with  IBD,
uch  as  cholangiocarcinoma,  lymphoma  and  skin  cancers
ay  occur  and  the  risk  is  increased  by  immunosuppres-
ive  treatments  [10—20].  A  meta-analysis  found  that  the
elative  risk  of  extra-intestinal  cancer  and  that  of  lym-
homa  by  comparison  with  the  standard  population  were
.27  (95%  conﬁdence  interval  [CI]:  1.1—1.47)  and  1.42  (95%
I:  1.16—1.73)  [19].
Multidetector  row  computed  tomography  (MDCT)  and
agnetic  resonance  (MR)  imaging  are  now  screening  modali-
ies  of  major  importance  for  diagnosing  complications  in  IBD
atients  as  well  as  problem-solving  tools  for  IBD  patients
resenting  with  unusual  symptoms  [2—4,8]. Consequently,
adiologists  are  currently  on  the  frontline  of  management
f  IBD  patients  in  many  occasions.  Because  of  the  rarity  of
xtra-intestinal  malignancies  in  IBD  patients,  knowledge  of
heir  imaging  features  is  based  on  case  reports  and  scarce
tudies  that  included  a  few  patients  [21—24].
The  goal  of  this  review  is  to  illustrate  the  MDCT  and  MR
maging  features  of  extra-intestinal  malignancies  that  occur
n  patients  with  IBD  and  provide  an  update  on  their  speciﬁc
athogenesis,  clinical  features  and  screening  recommenda-
ions,  if  any,  that  would  be  useful  to  the  radiologist.
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cholangiocarcinoma
ncidence, prevalence and risk factors
rimary  sclerosing  cholangitis  (PSC),  which  is  considered  as
n  intermediate  step  in  the  development  of  cholangiocarci-
oma  is  associated  with  IBD  in  60  to  80%  of  patients  [25].  UC
s  present  in  48  to  86%  of  patients  and  CD  in  13  to  25%  [25].
onversely,  PSC  is  the  most  common  hepatobiliary  complica-
ion  observed  in  IBD  patients  and  seen  in  approximately  5%
f  IBD  patients  [14,25—27].  CD  patients  have  a  less  marked
ncreased  risk  of  hepatobiliary  cancer  than  those  with  UC
10].
There  is  an  increased  risk  for  hepatobiliary  cancers  in
atients  with  UC,  including  biliary  tract  and  gallbladder  can-
ers  [12,28,29]  with  a  standardized  incidence  rate  (SIR)  of
.58  [10].  Of  note,  severe  dysplasia  or  adenocarcinoma  is
resent  in  approximately  60%  of  PSC  patients  with  polypoid
esions  of  the  gallbladder  [29].
In  IBD  patients,  the  estimated  incidence  of  cholangio-
arcinoma  is  between  0.5%  and  1%  [30].  The  incidence
ate  of  cholangiocarcinoma  in  IBD  patients  is  four  times
reater  than  that  in  patients  without  IBD  (7.6/100,000  vs.
.9/100,000,  respectively)  [14]  and  the  10-year  cumula-
ive  risk  of  cholangiocarcinoma  in  IBD  patients  is  0.07%.
his  increased  risk  is  more  prominent  in  patients  with  UC
han  in  those  with  CD,  with  an  incidence  rate  two  times
reater  for  UC  patients  than  for  CD  patients  (8.2/100,000
s.  4.3/100,000,  respectively)  [14].  Among  IBD  patients  with
holangiocarcinoma,  65%  have  deﬁnite  UC,  25%  have  deﬁnite
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specimens,  and  serum  tumor  markers  such  as  carbohydrate
antigen  (CA)  19—9  [43].  In  addition,  there  are  no  clear  rec-
ommendations  for  surveillance  to  date  but  regular  MDCT  and
Figure 1. A 52-year-old man with ulcerative colitis and primaryExtra-intestinal  malignancies  in  inﬂammatory  bowel  disease
CD  and  the  remaining  10%  have  an  undeterminate  diag-
nosis  [14].  Cholangiocarcinoma  occurs  at  a  younger  age  in
IBD  patients  than  in  the  general  population  without  IBD  (56
years  vs.  71  years,  respectively)  and  in  Western  countries,
cholangiocarcinoma  occurring  in  patients  ≤  40  y.o.  is  almost
always  associated  with  IBD  [14].  Of  major  importance,  the
risk  for  cholangiocarcinoma  is  dramatically  more  marked  in
IBD  patients  with  PSC,  which  is  160-fold  that  of  the  general
population  and  estimated  to  a  5%  -10%  lifelong  risk  [25].  The
peak  incidence  of  cholangiocarcinoma  is  observed  during  the
ﬁrst  years  following  the  diagnosis  of  IBD  [14].
Molecular features
The  mechanisms  of  carcinogenesis  in  PSC  are  not  well  elu-
cidated  yet.  The  evolution  from  PSC  to  cholangiocarcinoma
may  result  from  DNA  damage  by  bile  acids  in  IBD  patients
with  altered  DNA  repair  functions  (toxic  bile  hypothesis)
[31],  altered  functions  of  a  speciﬁc  cytokine  suppressor  [32]
or  altered  balance  between  macrophages  and  natural  killer
cells  [33].
Clinical and histological features
The  majority  of  IBD  patients  with  PSC  are  initially  asymp-
tomatic  with  only  biological  evidence  of  cholestasis  [34].
Symptoms  including  fatigue,  pruritus,  right  upper  quad-
rant  pain,  fever  and  weight  loss  develop  insidiously  [34].
Jaundice,  pruritus,  abdominal  pain  and  fatigue  are  more
frequently  observed  in  PSC  patients  who  will  develop  cholan-
giocarcinoma  than  in  those  who  will  not  [13].  A  high
proportion  of  cholangiocarcinomas  are  diagnosed  within  the
ﬁrst  year  after  the  diagnosis  of  PSC  is  made  [13]. The
development  of  PSC-associated  cholangiocarcinoma  follows
a  metaplasia-dysplasia-carcinoma  sequence.
Clinical implications
In  general,  UC  patients  with  coexisting  PSC  have  mild,
asymptomatic  colitis  that  spares  the  rectum,  so  that  colon
disease  may  be  undetected  during  rigid  sigmoidoscopy  [35].
As  a  consequence,  in  this  group  of  patients,  the  radiologist
should  scrutinize  the  colon  when  performing  MDCT  or  MR
imaging,  to  depict,  if  any,  ﬁndings  that  would  suggest  coex-
isting  IBD  [35,36].  However,  it  is  recommended  to  perform
colonoscopy  in  patients  with  PSC  and  UC.  In  addition,  the
risk  of  colon  cancer  is  very  high  in  this  population  so  that
the  radiologist  should  also  carefully  analyze  the  colon  wall.
The  major  cause  of  mortality  in  patients  with  PSC  is  the
occurrence  of  cholangiocarcinoma,  with  a  lifetime  incidence
of  10—15%  [35].  To  date,  no  validated  screening  tool  for  early
detection  of  cholangiocarcinoma  exists  so  that  cholangio-
carcinomas  are  often  diagnosed  at  an  advanced  stage.  The
diagnosis  of  cholangiocarcinoma  in  association  with  PSC  is
difﬁcult  and  delayed  because  abnormalities  of  the  biliary
tree  due  to  PSC  obscure  early  cholangiocarcinoma.
It  is  important  to  note  that  PSC  may  display  two  different
presentations.  PSC  may  involve  the  distal  biliary  ducts  in  the
absence  of  visible  abnormalities  on  MDCT  and  MR  imaging.
The  diagnosis  is  suggested  by  the  presence  of  altered  liver
function  tests.  This  form  in  association  with  IBD  is  observed
in  15%  of  patients,  has  a  better  long-term  survival  rate  and
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arries  a low  risk  for  cholangiocarcinoma  [25,37]. On  the
pposite,  PSC  may  involve  larger  bile  ducts,  including  intra-
epatic  ones  and  biliary  conﬂuence,  and  is  at  high  risk  of
alignant  transformation  [38].
Early  recognition  of  cholangiocarcinoma  can  be  made
y  measurement  of  trypsinogen-2  serum  level,  which  is
o  far  the  most  accurate  means  for  differentiating  PSC
rom  cholangiocarcinoma  [39]. Measurement  of  circulating
ngiopoietin-2  in  serum  may  be  an  additional  test  for  the
iagnosis  and  further  clinical  management  of  patients  with
holangiocarcinoma  [40].
The  diagnosis  of  cholangiocarcinoma  in  PSC  is  critical
ecause  the  tumor  has  a  rapid  growth.  In  addition  patients
ith  PSC  and  cholangiocarcinoma  may  beneﬁt  from  ortho-
opic  liver  transplantation  when  the  tumor  is  depicted  at
 very  early  stage  [41].  However,  the  question  of  ortho-
opic  liver  transplantation  remains  debated  because  best
esults  for  orthotopic  liver  transplantation  were  obtained
n  patients  with  PSC  and  incidental  depiction  of  cholangio-
arcinoma  in  explanted  liver.
Because  of  the  increased  risk  of  biliary  cancers  includ-
ng  gallbladder  cancers,  patients  with  IBD  and  PSC  should
e  investigated  with  ultrasonography  to  depict  gallbladder
olyps  every  year  and  cholecystectomy  should  be  performed
ven  when  polyps  <  1  cm  are  present  (Fig.  1) [31,42].
maging ﬁndings
arly  diagnosis  of  cholangiocarcinoma  in  PSC  is  difﬁcult
ecause  differentiating  between  benign  and  malignant  duc-
al  strictures  is  limited  with  current  imaging  modalities  such
s  ultrasonography,  MDCT,  MR  imaging,  endoscopy,  cytologyclerosing cholangitis. Ultrasonographic examination of the gall-
ladder reveals polypoid mass (arrows) with a largest diameter of
8 mm. After cholecystectomy, histopathological analysis conﬁrmed
allbladder polyp with foci of adenocarcinoma.
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R  imaging  examinations  and  repeat  endoscopic  brush  cytol-
gy  of  stenotic  lesions  are  recommended  [43]. It  is  assumed
hat  these  recommendations  should  help  detect  cholangio-
arcinoma  at  an  early  stage.  Of  note,  metastases  are  present
n  up  to  50%  of  patients,  supporting  the  fact  that  regular
urveillance  is  paramount  (Fig.  2)  [39,44—46].
The  diagnosis  of  cholangiocarcinoma  in  PSC  is  difﬁcult
ecause  the  tumor  has  often  a  longitudinal  growth  with  dis-
rete  perineural  and  perivascular  invasion  [47]  so  that  the
umor  is  often  not  directly  visible  on  imaging  at  an  early
tage.  In  this  regard,  the  diagnosis  of  cholangiocarcinoma
s  often  unexpected  and  made  during  pathological  analy-
is  of  explanted  liver  in  patients  treated  by  orthotopic  liver
ransplantation  [31].  For  that  reason  isolated  biliary  duct
ilatation  should  be  always  considered  as  suspect  until  the
iagnosis  of  cholangiocarcinoma  has  been  eliminated.
Ultrasonography  has  a  limited  role  for  the  diagnosis  of
holangiocarcinoma  in  IBD  patients.  The  role  of  ultrasono-
raphy  is  restricted  to  the  depiction  of  gallbladder  polyps
n  those  who  have  PSC  so  that  cholecystectomy  can  be  per-
ormed  at  an  early  stage  (Fig.  1)  [31,42].
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igure 2. A 55-year-old man with clinically and endoscopically quiesc
ped cholangiocarcinoma; a: MDCT in the axial plane obtained during the
aterial shows ill-deﬁned, heterogeneous liver lesions (arrows) with int
hows homogeneous circumferential thickening of the rectal wall (arrow
o ulcerative colitis.
igure 3. A 35-year-old man with ulcerative colitis and primary scler
he axial plane obtained during the arterial phase after intravenous adm
ell delineated mass (arrow) at the biliary conﬂuence with intrahepatic
xial plane obtained during the arterial phase after intravenous adminis
he hilar mass (arrow) with more marked intrahepatic bile duct dilatatio
ortal phase after intravenous administration of iodinated contrast mater
pstream bile duct dilatation (arrowhead). After orthotopic liver transp
holangiocarcinoma.A.  Dohan  et  al.
MDCT  has  a  sensitivity  of  82%  and  a  speciﬁcity  of  80%
or  the  diagnosis  of  cholangiocarcinoma  [48].  Usually  MDCT
hows  uni-  or  bilateral  intrahepatic  bile  duct  dilatation
Figs.  2  and  3).  The  tumor  itself  is  well  depicted  when
ts  presents  as  a  mass-forming  cholangiocarcinoma,  either
ntrahepatic  or  hilar.  Cholangiocarcinoma  presenting  as  a
tenosis  are  more  difﬁcult  to  depict  because  of  the  underly-
ng  PSC.  Multiplanar  reformatted  MDCT  images  help  better
ocalize  and  delineate  small  cholangiocarcinoma  (Fig.  3).  In
dvanced  stage  tumors,  MDCT  may  be  superior  to  MR  imaging
ecause  it  better  shows  abnormal  lymph  nodes  and  hepatic
arenchymal  involvement  [45,48,49].  In  addition,  MDCT  is
ore  accurate  than  MR  imaging  for  the  depiction  of  vascular
ncasement  [50].
MR  imaging  has  a  sensivity  of  virtually  100%  for  the
etection  of  mass-forming  cholangiocarcinoma  [49,50].  This
ategory  of  cholangiocarcinoma  is  usually  hyperintense  on
2-weighted  MR  imaging  and  poorly  enhancing  after  gadolin-
um  based  contrast  agents  (Fig.  4).  MR  cholangiography  is
quivalent  to  endoscopic  retrograde  cholangiography  for
he  diagnosis  of  PSC  [51—53].  MR  imaging  obtained  with
ent ulcerative colitis and primary sclerosing cholangitis who devel-
 portal phase after intravenous administration of iodinated contrast
rahepatic bile duct dilatation (arrowheads); b: MDCT of the pelvis
) with en bloc enhancement consistent with chronic changes due
osing cholangitis who developed cholangiocarcinoma; a: MDCT in
inistration of iodinated contrast material shows mildly enhancing,
 bile duct dilatation (arrowhead); b: one month later, MDCT in the
tration of iodinated contrast material shows slight enlargement of
n (arrowheads); c: MDCT in the coronal plane obtained during the
ial shows tumor mass (arrow) responsible for bile duct stricture and
lantation, histopathological analysis of explanted liver conﬁrmed
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intravenous  administration  of  a  gadolinium-chelate  in  com-
bination  with  MR  cholangiography  is  considered  as  the
best  imaging  modality  for  the  depiction  of  cholangiocarci-
noma  [31,48,52].  However,  because  it  is  sometimes  difﬁcult
to  discriminate  between  benign  and  malignant  stricture,
MR  cholangiography  alone  is  not  recommended  [48,54].
Cholangiocarcinoma  is  best  depicted  using  a  combination
of  T1-weighted  imaged  obtained  after  intravenous  admin-
istration  of  a  gadolinium-chelate  and  T2-weighted  images
[53,55]  (Fig.  4).  MR  cholangiography  shows  multifocal  stri-
ctures  along  with  dilatations  of  the  biliary  tree  [54].  Slightly
hyperintense  foci  of  hepatic  parenchyma  adjacent  to  bil-
iary  ducts  on  T2-weighted  images  that  are  hypointense
after  intravenous  administration  of  gadolinium-chelate  sug-
gest  the  presence  of  cholangiocarcinoma  [55,56].  Recently,
diffusion-weighted  MR  imaging  has  been  showed  to  improve
lesion  detection  because  of  markedly  restricted  diffusion
by  comparison  with  adjacent  hepatic  parenchyma  (Fig.  5)
[56].  The  EASL  and  the  AASLD  guidelines  recommend  MR
cholangiography  as  the  ﬁrst  line  imaging  examination  in
patients  with  suspected  PSC  [34].  However,  endoscopic  ret-
rograde  cholangiography  should  still  be  performed  when  MR
cholangiography  is  doubtful  or  inconclusive.  This  is  because
endoscopic  retrograde  cholangiography  may  depict  subtle
changes  that  are  not  visible  on  MR  cholangiography  [55].
In  addition,  MR  imaging  can  depict  gallbladder  carcinoma,
when  present,  as  hyperintense  foci  of  the  gallbladder  wall
on  T2-weighted  MR  images  [57].
18Fluoro-deoxy-glucose  (FDG)  positron  emission  tomogra-
phy  (PET)  CT  helps  depict  cholangiocarcinoma  not  seen  on
conventional  imaging  in  12%  of  patients  with  PSC  but  yields
false-positive  ﬁndings  [58,59].  This  technique  has  a  sensitiv-
ity  of  75%  and  a  speciﬁcity  of  95%  [58,59].  However,  the  role
of 18FDG-PET-CT  is  of  limited  value  because  when  the  tumor
Figure 4. A 24-year-old woman with ulcerative colitis and pri-
mary sclerosing cholangitis. Three-dimensional T1-weighted MR
image (repetition time/echo time, 5.4 ms/1.8 ms; ﬂip angle, 10◦)
obtained during the arterial phase after intravenous administration
of gadoterate meglumine (Dotarem®, Guerbet, Roissy-Charles-de-
Gaulle, France) shows heterogeneous, hypoenhancing tumor, with
peripheral rim of enhancement (arrow) and intrahepatic bile duct
dilatation (arrowheads) of the right liver.
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s  depicted  with  this  technique,  it  is  often  beyond  the  reach
f  curative  treatment  [58].
Best  results  for  the  diagnosis  of  cholangiocarcinoma
n  patients  with  PSC  are  obtained  with  a  combination
f  CA19-9  serum  measurement,  MR  cholangiography,  bil-
ary  brush  cytology  and 18FDG-PET-CT  [59]. For  speciﬁc
ases,  cholangioscopy  and  intrabiliary  ultrasonography  can
rovide  additional  information  by  comparison  with  endo-
copic  cholangiography  alone  [60].
epatocellular carcinoma
ncidence, prevalence and risk factors
o  date,  less  than  20  cases  of  hepatocellular  carcinoma
HCC)  in  IBD  patients  have  been  reported  so  that  the  asso-
iation  between  IBD  and  HCC  is  not  clearly  established
22,61—69]. All  of  them  were  observed  in  CD  patients  and
nly  two  cases  were  found  in  association  with  PSC  [68,69].
he  risk  of  HCC  in  patient  with  PSC  is  very  low  [70].
arginally,  one  UC  patient  was  reported  with  a  mix  tumor
i.e.,  hepatocholangiocarcinoma)  [71].  By  contrast,  four
ases  of  the  ﬁbrolamellar  variant  of  HCC  have  been  reported
nd  all  were  found  in  UC  patients  [22,72].  Snook  et  al.  have
eported  one  case  of  well-documented  ﬁbrolamellar  variant
f  HCC  in  one  patient  with  UC  and  PSC  [22].
Prolonged  treatment  by  azathioprine  has  been  advocated
s  a  risk  factor  for  the  development  of  HCC  because  the
ajority  of  patients  were  receiving  this  treatment  at  the
ime  HCC  was  diagnosed  or  because  they  had  received
zathioprine  before  [21,62—64,66—69]. However,  HCC  may
evelop  in  patients  who  did  not  receive  azathioprine  [61].
t  is  acknowledged  that  the  small  number  of  reported  cases
oes  not  allow  drawing  ﬁrm  conclusions  and  the  association
ay  be  only  fortuitous.  Of  interest,  a  majority  of  HCCs  were
bserved  in  the  absence  of  any  risk  factor  for  the  develop-
ent  of  this  tumor,  including  the  absence  of  chronic  diffuse
iver  disease  [61,65]  and  only  a  few  developed  in  the  pres-
nce  of  an  underlying  chronic  diffuse  disease  [68,69].
olecular features
ll  but  one  cases  of  HCC  occurred  in  CD  patients  who  were
eceiving  azathioprine  [61].  It  may  be  thus  possible  that  aza-
hioprine  may  cause  direct  toxicity  and  mutagenic  effects
nd  favor  the  occurrence  of  HCC.  However,  the  actual  role  of
zathioprine  remains  debated  and  other  mechanisms,  such
s  focal  hepatic  glycogenosis,  may  favor  the  development
f  HCC  in  CD  patients  [65,66]. In  this  regard,  the  associa-
ion  of  azathioprine  and  focal  hepatic  glycogenosis  has  been
eported  in  four  CD  patients  with  HCC  in  the  absence  of
irrhosis  or  PSC  [65,66].
linical and histological features
ll  CD  patients  with  HCC  were  negative  for  viral  hepati-
is  test  or  liver  cirrhosis.  Only  two  HCCs  developed  in  CD
atients  with  CD  and  PSC  [68,69]. CD  patients  with  HCC
re  younger  (mean  age:  35  years)  than  the  standard  pop-
lation  with  HCC  [21,61].  The  majority  of  HCC  were  found
n  patients  with  quiescent  CD  that  mostly  involved  the  colon.
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Figure 5. A 69-year-old man with ulcerative colitis and primary sclerosing cholangitis who developed hilar cholangiocarcinoma; a: T2-
weighted MR image (HASTE; TR/TE = 1000/96 ms; ﬂip angle = 180◦) in the axial plane shows hypointense lesion (arrowhead) at the hepatic
hilum with upstream dilatation of right main bile duct (arrow); b: three-dimensional MR cholangiography in the coronal plane shows
hilar stenosis (arrow) of intrahepatic bile ducts; c: diffusion-weighted MR image (single-shot echo-planar imaging, TR/TE = 3900/91 ms;
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P = 800 s/mm2) in the axial plane shows hyperintense focal mass with
nalysis revealed cholangiocarcinoma.
CC  developed  approximately  15.1  years  after  the  onset  of
D  (range:  6—36  years)  [21,65,66].
HCC  in  IBD  patients  have  a  variable  histopathologi-
al  presentation,  ranging  from  well-differentiated  tumors
ith  trabecular  pattern  [61,65]  to  poorly  differentiated
CC  with  pleomorphic  cellular  changes  [21,64,67].  Some  of
hem  were  found  adjacent  to  focal  hepatocyte  glycogenosis
21,67].  The  ﬁbrolamellar  variant  is  exceedingly  rare  [22].
There  is  no  well-deﬁned  treatment  because  of  the  rar-
ty  of  the  disease.  Several  options  are  available,  including
artial  hepatic  resection  [21,64,65],  orthotopic  liver  trans-
lantation  [22],  chemoembolization  for  advanced  disease
61]  of  systemic  chemotherapy  alone  for  advanced  stages
68].
maging ﬁndings
n  imaging,  HCC  in  IBD  patients  may  present  as  a  single,
mall,  encapsulated  hypervascular  nodule  during  the  arte-
ial  phase  of  enhancement  on  MDCT  and  MR  imaging  with  a
ypical  ‘‘wash-out’’  on  the  following  phases  similar  to  the
ndings  observed  in  the  more  common  cirrhosis-related  HCC
Fig.  6)  [61,73—75].  HCC  presenting  as  a  single  nodule  has  a
iameter  ranging  from  2.3  to  8  cm  and  are  uniformly  located
n  the  right  liver  [21,67].  A  peripheral  rim  of  enhance-
ent  has  been  described  in  one  patient  (Fig.  6)  [67]. Some
uthors  have  reported  predominantly  necrotic  HCC  [66].  On
R  imaging,  the  tumor  is  hyperintense  on  T2-weighted  MR
mages  (Fig.  6)  [67].  Rarely,  the  tumor  can  be  bifocal  or
ay  present  as  multiple  nodules  of  various  size  and  vari-
ble  degrees  of  enhancement  [61,62,64].  Portal  invasion  by
umor  has  been  reported  in  one  patient  [64].  There  is  no
vidence  of  underlying  liver  cirrhosis  or  PSC  on  imaging  in
he  majority  of  cases  [21,65].
The  imaging  features  of  the  ﬁbrolamellar  variant  of  HCC
n  IBD  patient  have  been  reported  only  once  [22]. The
uthors  made  a  brief  description  of  CT  ﬁndings  and  indicated
hat  the  tumor  that  developed  in  a  UC  patient  presented  as
n  irregular  and  mildly  enhancing  centrohepatic  mass  with
ultiple  accompanying  satellite  malignant  nodules  [22].
I
c
iricted diffusion consistent with malignant lesion. Histopathological
his  presentation  is  different  from  the  typical  ﬁndings  of
his  speciﬁc  tumor  (Fig.  7) [76].
ematological malignancies
ncidence, prevalence and risk factors
ematological  malignancies  in  IBD  patients  consist  predom-
nantly  of  non-Hodgkin  lymphoma  but  Hodgkin  lymphoma
nd  chronic  leukemia  have  been  reported  as  well  [18,19].
lthough  lymphomas  in  IBD  patients  can  involve  the  gas-
rointestinal  tract  [77—79]  they  can  also  be  extra-intestinal
18,19,80—83]. Extra-intestinal  lymphoma  in  IBD  patients
an  be  observed  UC  and  CD  patients  [79].  In  CD  patients,
here  is  an  increased  risk  for  Hodgkin  and  non-Hodgkin  lym-
homa,  with  a  standardized  incidence  rate  of  1.42  (95%CI:
.16—1.73)  [19]. In  UC  patients  there  is  an  increased  risk  for
hronic  leukemia,  with  a  standardized  incidence  rate  of  2.0
95%CI:  1.31—3.06)  [10].
The  risk  of  lymphoma  or  acute  myeloid  leukemia  in  IBD
atients  is  increased  by  the  use  of  azathioprine  or  other
urines  with  an  increased  risk  3  to  5-fold-higher  than  in  the
eneral  population  [18,84—86].
It  is  also  very  likely  that  tumor  necrosis  factor  inhibitors
ay  increase  the  risk  of  lymphoproliferative  disorders  in
BD  patients  [87—89]. There  are  some  studies  that  suggest
n  association  between  Epstein-Barr  virus  (EBV)  infection
nd  hepatosplenic  T-cell  lymphoma  in  IBD  patients  receiv-
ng  an  association  of  TNF-alpha  inhibitors  and  thiopurine
85,86,90—92].
The  association  between  CD  and  myeloproliferative  dis-
rders  has  been  reported  in  several  case  reports  [93]  and
n  a cohort  study  [94]  but  there  is  no  clearly  demonstrated
ncreased  risk  for  IBD  patients.
athogenesist  is  currently  difﬁcult  to  individualize  a  speciﬁc  causative
ondition  for  hematological  malignancies.  Inﬂammation,
mmune  activation,  azathioprine,  EBV  infection  may  be
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Figure 6. A 45-year-old man with ulcerative colitis who developed hepatocellular carcinoma in the absence of underlying hepatic disease.
a: three-dimensional T1-weighted MR image (3D VIBE; repetition time/echo time = 5.4 ms/1.8 ms; ﬂip angle, 10◦) obtained during the
arterial phase after intravenous administration of gadoterate meglumine (Dotarem®, Guerbet, Roissy-Charles de Gaulle, France) shows
hyperenhancing focal liver lesion (arrow); b: during the portal phase, the lesion shows peripheral rim of enhancement (arrowheads); c:
during the late phase, the lesion (arrow) becomes hypointense relative to the adjacent hepatic parenchyma; d: diffusion-weighted MR
0 s/m
ical a
C
Timage (single-shot echo-planar imaging, TR/TE = 3900/91 ms; b = 80
restricted diffusion consistent with malignant lesion. Histopatholog
responsible  for  an  increased  risk  [18,95].  EBV  infection
may  have  an  intermediate  role  between  immunosuppressive
treatment  and  lymphoma  [18].  It  has  also  been  suggested
that  Helicobacter  pylori  may  play  a  role  in  the  development
of  lymphoma  [18].
d
[
Figure 7. A 32-year-old man with Crohn disease who developed ﬁbr
obtained during the arterial phase after intravenous administration of io
mass (arrows) located in the left liver; b: MDCT in the axial plane obt
the liver mass (arrows); c: after left hepatectomy, gross examination sh
conﬁrmed as ﬁbrolamellar hepatocellular carcinoma.m2) in the axial plane shows hyperintense focal liver lesion with
nalysis revealed well-differentiated hepatocellular carcinoma.
linical and histological features
he  clinical  presentation  of  IBD-related  lymphoproliferative
isorders  do  not  differ  from  that  of  patients  without  IBD
18].
olamellar hepatocellular carcinoma; a: MDCT in the axial plane
dinated contrast material shows large, heterogeneously enhancing
ained during the portal phase shows incomplete enhancement of
ows suggestive central scar (arrowheads). The tumor was further
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Regarding  lymphoma,  three  main  types  have  been
eported  in  association  with  azathioprine  treatments.  They
onsist  of  EBV-related  post-transplant  like  lymphoma,  hep-
tosplenic  T-cell  lymphoma  and  post-mononucleosis  lym-
hoproliferation  [18,89].  Azathioprine  has  been  particularly
mplicated  in  IBD-associated  lymphoproliferative  disorders
isk.  Along  with  immunosuppressive  effect,  it  is  assumed
hat  azathioprines  may  have  speciﬁc  pro-carcinogenic
ffects.  It  has  been  suggested  that  azathioprine  may  pro-
ote  clonal  expansion  of  rare  mismatch  repair-defective
yeloid  cells,  thus  possibly  playing  a  role  in  the  develop-
ent  of  some  hematological  malignancies  [17].
IBD  patients  presenting  with  mesenteric  masses  have
ften  a  diffuse  large  B-cell  type  lymphoma  that  is  more
elated  to  EBV  virus  [18].
linical implications
o  date,  there  is  no  speciﬁc  test  for  an  early  diagnosis  of
ematological  malignancies  in  IBD  patients  [18].  Thiopurines
hould  be  avoided  in  young  men  who  are  seronegative  for
BV  [17,18].  Similarly,  it  is  recommended  to  avoid  the  asso-
iation  of  TNF-alpha  inhibitors  and  thiopurine  for  more  than
wo  years  in  young  men  [18].
maging ﬁndings
o  speciﬁc  imaging  ﬁndings  have  been  reported  for  extra-
ntestinal  lymphoproliferative  disorders  in  IBD  patients  so
ar.  On  imaging,  lymphoma  in  IBD  patients  has  the  same  pre-
entation  than  that  of  lymphoma  in  patients  without  IBD.
ymphomas  can  be  mesenteric  [83],  pulmonary  [81,96]  and
epatosplenic  [85,91,97,98].  Percutaneous  biopsy  is  recom-
ended  to  make  a  deﬁnite  diagnosis  [96,99].
Extra-intestinal  lymphomas  usually  present  as  multiple
nlarged  lymph  nodes,  mainly  in  the  mesentery  (Fig.  8)
100—102]  but  more  rarely  they  can  present  as  a  sin-
le  enlarged  lymph  node  [83].  On  MDCT,  enlarged  lymph
odes  are  usually  homogeneous  and  may  encase  mesen-
eric  vessels  [100—102].  On  MR  imaging,  mesenteric  masses
ue  to  lymphoma  are  hypointense  relative  to  fat  and
lightly  hyperintense  relative  to  muscle  on  T1-weighted
R  images  but  isointense  or  hypointense  relative  to  fat
nd  hyperintense  relative  to  muscle  on  T2-weighted  MR
mages  (Fig.  8)  [100,101].  Radiologists  should  therefore  give
pecial  attention  to  enlarged  mesenteric  lymph  nodes  in
oung  IBD  patients  treated  with  immunosuppressive  ther-
pies  and  warn  clinicians  of  a  potential  development  of
n  underlying  lymphoproliferative  disease.  Other  locations
uch  as  the  thorax  have  been  reported  [81,96].  Thoracic
odgkin  lymphomas  in  CD  patient  may  present  as  a single,
ound,  spiculated  intrapulmonary  nodule  on  CT  [81].  How-
ver,  Rodriguez  et  al.  have  reported  one  case  of  thoracic
odgkin  lymphoma  presenting  as  a  large  (15  ×  9  ×  9  cm),
ediastinal  mass  that  encased  the  left  pulmonary  artery
96].
Extra-intestinal  lymphoma  may  also  present  as  hepatic
nd  or  splenic  nodules,  which  are  predominantly  hypoe-
hogenic  on  ultrasonography  [103].  On  MR  imaging  they
resent  as  focal  hepatic  lesions  of  various  dimensions  (from
 mm  to  15  cm),  which  usually  have  a  low  signal  intensity
n  T1-weighted  MR  images  and  variable  signal  intensity  on
d
o
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2-weighted  MR  images  [104,105].  A  mild  rim  of
nhancement  after  intravenous  administration  of
adolinium-chelate  is  observed  in  60%  of  lesions  [105].
Marginally,  Winnicki  et  al.  have  reported  one  case  of
odgkin  lymphoma  that  presented  as  a  large  vulvar  and
erineal  mass  in  a  45-year-old  woman  with  CD  [106].  Imag-
ng  disclosed  a  large  mass  (20  ×  20  cm)  involving  the  labia
ajora  and  the  perineum  in  association  with  multiple  lymph
odes  and  liver  involvement  [106].
18FDG-PET-CT  has  a  well-established  role  in  the  assess-
ent  of  diffuse  large  B-cell  and  Hodgkin  lymphomas
107,108].  It  is  currently  recommended  as  part  of  the  initial
ssessment  of  the  disease  [107,108].
iscellanous malignancies
kin cancers
he  incidence  of  non-melanoma  skin  cancer  is  greater  in
BD  patients  by  comparison  with  patients  without  IBD  (inci-
ence  rate  ratio:  1.64;  95%  CI:  1.51—1.78)  [109—111].  The
isk  is  greater  for  those  receiving  thiopurines  [109,110].
he  most  common  cutaneous  malignancies  in  IBD  patients
nclude  squamous  cell  carcinoma  and  basal  cell  skin  cancer,
hereas  melanoma  is  less  frequent.  The  risk  for  squamous
ell  carcinoma  is  greater  for  CD  patients,  with  a  SIR  of  2.35
95%CI:  1.43—3.86)  than  for  UC  patients  with  a  SIR  of  1.68
95%CI:  0.90—3.12)  [10].  Conversely,  the  risk  for  melanoma
s  slightly  less  marked  for  CD  patients,  with  a  SIR  of  1.35
95%CI:  0.65—2.82)  than  for  UC  patients  with  a  SIR  of  1.56
95%CI:  0.80—3.05)  [10].
Thiopurines  (including  6-mercaptopurine  and  azathio-
rine)  are  associated  with  an  increased  photosensitivity
o  ultraviolet  A  light  [110].  The  risk  of  skin  cancer  per-
ists  even  after  discontinuation  of  the  thiopurines,  possibly
ecause  the  damage  resulting  from  the  increased  ultravi-
let  light  sensitivity  has  already  occurred  and  cannot  be
eversed  [111].  Use  of  anti-tumor  necrosis  factor  therapy  is
lso  associated  with  a  slightly  increased  risk  of  melanoma,
ut  there  are  no  data  to  determine  whether  duration  of  use
ffects  this  risk  [110]. In  addition,  the  mechanism  underly-
ng  the  increased  risk  of  melanoma  requires  further  study
110].
Imaging,  including  MDCT  at  the  time  of  initial  diagnosis
f  T1b—T3b  melanoma,  clinically  N0,  M0  melanoma  has  of
ow  yield  with  a  high  false-positive  rate,  and  does  not  lead
o  upstaging  or  change  in  initial  surgical  management  [112].
t  is  suggested  that  imaging  of  asymptomatic  patients  at  the
ime  of  diagnosis  may  not  be  warranted  [112].
On  MR  imaging,  liver  metastases  from  melanoma  are
yperintense  on  T1-weighted  MR  images  because  of  melanin
ontent  and  hypervascular  on  the  early  phase  after  intra-
enous  administration  of  a  gadolinium-chelate  [113].  For  the
nitial  evaluation,  MR  imaging  has  a  sensitivity  of  up  to  100%
or  the  detection  of  hepatic  metastases  from  melanoma  on
 per  lesion  basis,  which  is  greater  than  that  of 18FDG-PET-
T,  which  is  47%  [113]. The  limitation  of 18FDG-PET-CT  is  the
ifﬁculty  to  depict  small  metastases  [113].
18FDG-PET-CT  is  not  recommended  for  the  initial  staging
f  stage  I  and  stage  II  melanoma  [114]  but  is  recommended
n  stage  III  and  stage  IV  [115].
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Figure 8. A 45-year-old man with Crohn disease who developed non-Hodgkin lymphoma during treatment with azathioprine; a: MDCT
in the axial plane obtained during the enteric phase after intravenous administration of iodinated contrast material shows enhancing,
homogeneous mesenteric mass (arrows) encasing left lateral branch (arrowhead) of superior mesenteric artery; b: MDCT in the coronal plane
conﬁrms presence of large, homogeneously enhancing mesenteric mass (arrows) that encases jejunal vessels. Cluster of enlarged mesenteric
lymph nodes (arrowheads) are observed at the upper pole of the mass, adjacent to porta hepatis; c: T2-weighted MR image (HASTE,
TR/TE = 1000/96 ms, ﬂip angle = 180◦) obtained in the coronal plane shows hypointense mesenteric mass (arrows); d: three-dimensional
T1-weighted MR image (3D VIBE; TR/TE = 4.68/1.6 ms; ﬂip angle = 16◦) obtained during the enteric phase after intravenous administration
aulle
v
i
c
C
E
e
g
d
t
w
m
i
aof gadoterate meglumine (Dotarem®, Guerbet, Roissy-Charles-de-G
engorged mesenteric vessels (arrowheads).
Cervical dysplasia and cervical malignancies
Immunosuppression  results  in  a  higher  incidence  of  cervical
dysplasia  compared  with  healthy  control  females  [116]. The
incidence  of  abnormal  Papanicolaou  smear  in  IBD  woman
is  42.5%  vs.  7%  in  controls  (P  <  0.001)  [116].  Women  with
IBD  are  more  likely  to  have  higher-grade  lesions  than  con-
trols  (P  <  0.001)  [116].  In  addition,  IBD  women  who  had
received  immunosuppressive  treatment  are  more  likely  to
have  an  abnormal  Papanicolaou  smear  (P  <  0.001)  than  con-
trols  [10].
The  risk  of  cervical  cancer  in  IBD  women  is  1.15  (95%CI:
0.58—2.29)  with  no  difference  between  CD  and  UC  women
[10].
It  is  now  well  admitted  that  the  follow-up  of  IBD  should
follow  the  American  College  of  Obstetrics  and  Gynecology
screening  guidelines  for  immunocompromised  individuals
[18].  Human  papillomavirus  vaccine  should  be  performed  in
all  IBD  women  between  9  and  26  years  before  starting  sexual
activity  [18].
a
k
d
p, France) shows mildly enhancing mesenteric mass (arrows) with
No  speciﬁc  imaging  features  have  been  reported  for  cer-
ical  cancers  in  IBD  women  [117].  MR  imaging  is  currently  the
maging  modality  of  choice  for  the  initial  staging  of  cervical
ancer  [118].
onclusion
xtra-intestinal  malignancies  in  IBD  patients  are  not
xceptional.  Intrahepatic  malignancies  such  as  cholan-
iocarcinoma  and  hepatocellular  carcinoma  are  often
iagnosed  at  an  advanced  stage,  resulting  in  only  palliative
reatment  in  a  substantial  number  of  patients.  Radiologists
ho  at  the  front  line  in  the  investigation  of  IBD  patients
ust  keep  in  mind  that  IBD  may  be  associated  with  extra-
ntestinal  malignancies,  especially  in  IBD  patients  with  PSC
nd  those  who  have  longstanding  immunosuppressive  ther-
pies,  which  are  likely  to  favor  carcinogenesis.  A  better
nowledge  of  these  speciﬁc  imaging  features  should  help
etect  extra-intestinal  malignancies  at  an  early  stage,  thus
resumably  improving  patient  prognosis.
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